Skip to content
Screener

Trevi Therapeutics, Inc. TRVI Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Savara logo
SavaraSVRA
-$40.33M-34.5%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
-$39.93M+0.4%

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.64B+196%
Enterprise value$2.62B+238%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×
Current ratio24.8×+9.4×

Where this comes from

Reported directly by Trevi Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:09 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206390
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Income tax benefit(20)(11)
Net loss$(13,192)$(10,340)
Basic and diluted net loss per common share outstanding$(0.09)$(0.09)
Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted145,592,901117,610,750
Net loss$(13,192)$(10,340)
Other comprehensive (loss) income:
Net unrealized (losses) gains on available-for-sale marketable securities(338)12
Comprehensive loss$(13,530)$(10,328)

Item 1. Condensed Consolidated Financial Statements.

FAQ

What is Trevi Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Trevi Therapeutics, Inc. (TRVI) reported comprehensive income (loss), net of tax, attributable to parent of -$13.53M in Q1 2026.
How has Trevi Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Trevi Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 31.0% year-over-year, from -$10.33M to -$13.53M.
What is the long-term trend for Trevi Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 5.9% compound annual growth rate (CAGR), from -$33.94M to -$42.67M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
Measures the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items. It provides a broader view of financial performance than net income alone by incorporating unrealized gains or losses. This metric is essential for understanding the total economic impact on shareholder equity.

Ask your AI about Trevi Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude